Cancer treatment has improved dramatically over the last decade, giving many patients a better chance of surviving diseases that were once considered very difficult to treat.
One of the biggest breakthroughs has been the development of immunotherapy, a type of treatment that helps the body’s own immune system find and attack cancer cells.
Among the most successful forms of immunotherapy are medicines known as immune checkpoint inhibitors.
These treatments have transformed care for many cancers and have extended the lives of countless patients around the world.
Despite these benefits, immune checkpoint inhibitors are not perfect. While they help the immune system attack tumors, they can sometimes cause the immune system to become overactive and attack healthy tissues as well.
In some patients, this can lead to inflammation in the heart and blood vessels. These complications can become serious and may force doctors to stop cancer treatment early. When treatment is interrupted, tumors may begin growing again, creating a difficult situation for both patients and healthcare providers.
Researchers have therefore been searching for better ways to monitor both cancer and heart health at the same time. Scientists from Washington University in St. Louis have now developed a promising new approach that may help solve this problem. Their work was presented at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting.
The researchers focused on a protein called CCR2. This protein is found in inflammatory cells that gather in tumors as well as in areas of inflammation inside blood vessels. Because CCR2 appears in both places, the scientists believed it might serve as a useful marker for tracking cancer activity and cardiovascular inflammation simultaneously.
To test this idea, the team used a specialized PET imaging technique. PET scans are advanced imaging tools that allow doctors to see biological processes happening inside the body. Unlike traditional scans that mainly show anatomy, PET imaging can reveal how cells behave and where disease activity is occurring.
The researchers used a new imaging tracer called 64Cu-DOTA-ECL1i, which was designed to attach to CCR2. When the tracer binds to CCR2-containing cells, it creates a signal that can be detected by PET scanners. This allows scientists to visualize inflammation and tumor activity in real time.
The study used mice that had both atherosclerosis, a disease involving inflammation in the arteries, and oral cancer tumors. This combination allowed researchers to create a model that reflected the challenges often faced by cancer patients who also have cardiovascular disease.
One group of mice received immune checkpoint inhibitor treatment, while another received a comparison treatment. The researchers performed PET scans throughout the study and compared the new imaging method with a commonly used PET scan known as FDG PET.
The new CCR2-targeted scan performed remarkably well. It produced clearer images of both tumors and inflamed artery plaques than the traditional imaging method. The results also revealed an important finding. While immune checkpoint therapy slowed tumor growth, it increased inflammation-related signals in the heart and blood vessels.
The researchers then tested a second strategy. They combined the cancer treatment with a medicine called itacitinib. This drug blocks a biological pathway involved in inflammation.
Mice receiving the combination therapy showed better tumor control and significantly lower levels of cardiovascular inflammation. The scans also revealed fewer inflammatory cells in the arteries.
These findings suggest that doctors may eventually be able to use one imaging test to monitor both cancer response and cardiovascular side effects during treatment. This could help identify patients who are developing heart-related complications before symptoms appear.
The discovery may be particularly important because cardiovascular problems caused by immunotherapy can sometimes develop silently. Detecting these changes early could allow doctors to adjust treatment and prevent severe complications such as heart attacks or myocarditis.
The study also points toward a future in which cancer treatment becomes more personalized. Rather than waiting for side effects to appear, doctors may be able to monitor individual patients more closely and tailor therapies based on what the scans reveal.
The findings are especially encouraging because the imaging tracer used in the study is already being evaluated in clinical trials for several diseases. This means the technology could potentially reach patients relatively quickly if future studies confirm its value.
When reviewing the findings, the study appears highly innovative because it addresses two major medical concerns at the same time: controlling cancer and protecting the heart. The results suggest that CCR2 imaging may provide a practical way to detect cardiovascular inflammation before serious damage occurs.
The combination therapy findings are also promising because they suggest it may be possible to improve cancer outcomes while reducing harmful side effects.
However, the research was conducted in animals, and larger human studies will be needed before the approach can become part of routine medical care. Even so, the work represents an important step toward safer and more personalized cancer treatment.
If you care about cancer, please read studies that a low-carb diet could increase overall cancer risk, and berry that can prevent cancer, diabetes, and obesity.
For more health information, please see recent studies about how drinking milk affects the risks of heart disease and cancer and results showing vitamin D supplements could strongly reduce cancer death.
